Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

While much progress has been made in the fight against the scourge of tuberculosis (TB), we are still some way from reaching the ambitious targets of eliminating it as a global public health problem by the mid twenty-first century. A new and effective vaccine that protects against pulmonary TB disease will be an essential element of any control strategy. Over a dozen vaccines are currently in development, but recent efficacy trial data from one of the most advanced candidates have been disappointing. Limitations of current preclinical animal models exist, together with a lack of a complete understanding of host immunity to TB or robust correlates of disease risk and protection. Therefore, in the context of such obstacles, we discuss the lessons identified from recent efficacy trials, current concepts of biomarkers and correlates of protection, the potential of innovative clinical models such as human challenge and conducting trials in high-incidence settings to evaluate TB vaccines in humans, and the use of systems vaccinology and novel technologies including transcriptomics and metabolomics, that may facilitate their utility.

Original publication

DOI

10.1080/21645515.2015.1134407

Type

Journal article

Journal

Hum Vaccin Immunother

Publication Date

03/05/2016

Volume

12

Pages

1177 - 1187

Keywords

BCG, MVA85A, Mycobacterium tuberculosis, clinical models, clinical trials, tuberculosis, vaccine, Animals, BCG Vaccine, Biomarkers, Clinical Trials as Topic, Disease Models, Animal, Drug Design, Gene Expression Profiling, Humans, Metabolomics, Mycobacterium tuberculosis, Tuberculosis, Tuberculosis Vaccines, Tuberculosis, Pulmonary, Vaccination